Analyst Alerts: Biogen, Accretive Health, Teradata, MDC Holdings April 30th

Biogen Idec Inc. (NASDAQ:BIIB): Deutsche Bank raised its price target for Biogen shares after its survey indicated 40%-57% of patients taking Baxter’s (NYSE:BAX) Advate would consider switching to Biogen’s hemophilia treatment. The firm keeps a Buy rating on Biogen shares.

Accretive Health, Inc. (NYSE:AH): Piper Jaffray lowered its estimates and price target for Accretive Health after Fairview dropped the company for its QTCOC contract, Senator Al Franken vowed to investigate the company, and a local newspaper reported questionable financial ties to Accretive Health by Fairview executives. Piper believes recent events pose a risk to Accretive Health’s customer renewals and new contract wins. The firm reiterates an Underweight rating on the stock.

Teradata Corporation (NYSE:TDC): Shares were removed due to an automatic time demotion.

MDC Holdings Inc. (NYSE:MDC): M.D.C. Holdings added to the short-term buy list at Deutsche Bank

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.